Staying ahead of the investment curve is increasingly challenging.
The professionals at Leigh Baldwin & Co. have the experience and expertise to guide you through the maze of available options.
With our competitive pricing, investment selection, and an office near you, a no-cost obligation “2nd opinion” may be just the investment your portfolio needs. Click here to view all of the services provided by Leigh Baldwin & Co.
Day Traders Diary
Diamonds and Dogs
Day Traders Diary
The major averages came under pressure today even as earnings keep rolling in from corporate America. Profit-taking persisted with the recent highflyers including artificial intelligence stocks. The Dow Jones Industrial Average fell 398 points, or 0.84%. The S&P 500 fell 75 points or 1.1% while the Nasdaq fell 445 points
Industrials continue to perform well. Engine maker, Cummins (CMI) is up 6% after easily beating earnings estimates while sales fell 1.6% to $8.32 billion, ahead of estimates. Cummins did not provide any guidance but expects their strong third quarter results to persist as demand remains strong for their power systems
Drug stock, Amgen (AMGN) is performing well. The stock is up 5% after easily beating earnings estimates. Sales rose 12% to $9.56 billion. The company raised guidance reflecting robust volume-driven by key medicines like repatha, evenity and tezspire along with rare disease and biosimilar drugs. Regarding their pipeline, Amgen accelerated
The major averages came under pressure today even as earnings keep rolling in from corporate America. Profit-taking persisted with the recent highflyers including artificial intelligence stocks. The Dow Jones Industrial Average fell 398 points, or 0.84%. The S&P 500 fell 75 points or 1.1% while the Nasdaq fell 445 points
Diamonds and Dogs
Industrials continue to perform well. Engine maker, Cummins (CMI) is up 6% after easily beating earnings estimates while sales fell 1.6% to $8.32 billion, ahead of estimates. Cummins did not provide any guidance but expects their strong third quarter results to persist as demand remains strong for their power systems
Drug stock, Amgen (AMGN) is performing well. The stock is up 5% after easily beating earnings estimates. Sales rose 12% to $9.56 billion. The company raised guidance reflecting robust volume-driven by key medicines like repatha, evenity and tezspire along with rare disease and biosimilar drugs. Regarding their pipeline, Amgen accelerated
Current Market Headlines
Yahoo! News: Economy News
